Filter By Category
Archives
Share on -
ANDEXANET ALFA
Generic Name: ANDEXANET ALFA
ABSTRACT -
Andexanet alfa is a recombinant modified human factor Xa decoy protein used to reverse anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding where approved. It binds factor Xa inhibitors with high affinity, reducing their anti-Xa activity while lacking normal factor Xa catalytic function.
DOSAGE -
- Dosage should be determined only by a qualified emergency, hematology, or critical-care professional.
- Approved regimens use a low-dose or high-dose intravenous bolus followed by a two-hour infusion.
- Dose selection depends on the specific factor Xa inhibitor, the last inhibitor dose, and the time since the last dose.
- Restarting anticoagulation should be considered as soon as medically appropriate after bleeding control.
SIDE EFFECTS–
- Possible side effects include:
- Thromboembolic events
- Infusion-related reactions
- Fever
- Flushing
- Hypotension
- Nausea
- Headache
- Rebound or recurrent anticoagulation effect
- Possible cardiac, stroke, or venous thrombotic events
ALLRGIC REACTIONS–
- Possible allergic reaction symptoms include:
- Rash
- Urticaria
- Facial swelling
- Bronchospasm
- Anaphylaxis symptoms
- Important: Patients who develop an allergic reaction to Andexanet Alfa should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
- Heparin responsiveness may be reduced after andexanet alfa; avoid use before planned heparinization when possible.
- Concurrent anticoagulants, antiplatelets, or thrombolytics affect bleeding and thrombosis balance.
- Procoagulant reversal agents may increase thrombotic risk.
- Laboratory anti-Xa activity may not perfectly predict clinical hemostasis.
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Use only for serious bleeding after confirmed or suspected apixaban/rivaroxaban exposure.
- Monitor for thrombosis, recurrent bleeding, and hemodynamic instability.
- Use caution in patients with recent thrombosis, stroke, myocardial infarction, or high thrombotic risk.
- Plan post-reversal anticoagulation strategy once clinically safe.
WARNINGS –
- Thrombotic events, ischemic events, cardiac arrest, and sudden death have been reported after reversal.
- Emergency support and specialist assessment are required.
- Not for routine reversal before procedures unless benefit clearly outweighs risk.
- Keep out of reach of children.
Share on -
. Developed by